🚀 VC round data is live in beta, check it out!
Henlius Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Henlius Biotech and similar public comparables like Hebei Changshan, Abbott India, Erasca, Mirum Pharmaceuticals and more.
Henlius Biotech Overview
About Henlius Biotech
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Founded
2010
HQ
Employees
3.5K
Website
Sectors
Financials (LTM)
EV
$6B
Henlius Biotech Financials
Henlius Biotech reported last 12-month revenue of $1B and EBITDA of $212M.
In the same LTM period, Henlius Biotech generated $765M in gross profit, $212M in EBITDA, and $136M in net income.
Revenue (LTM)
Henlius Biotech P&L
In the most recent fiscal year, Henlius Biotech reported revenue of $839M and EBITDA of $197M.
Henlius Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $839M | XXX | XXX | XXX |
| Gross Profit | $765M | XXX | $613M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $212M | XXX | $197M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $136M | XXX | $120M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | — | — | $392M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Henlius Biotech Stock Performance
Henlius Biotech has current market cap of $6B, and enterprise value of $6B.
Market Cap Evolution
Henlius Biotech's stock price is $10.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $6B | 1.8% | XXX | XXX | XXX | $0.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHenlius Biotech Valuation Multiples
Henlius Biotech trades at 6.2x EV/Revenue multiple, and 29.6x EV/EBITDA.
EV / Revenue (LTM)
Henlius Biotech Financial Valuation Multiples
As of April 19, 2026, Henlius Biotech has market cap of $6B and EV of $6B.
Equity research analysts estimate Henlius Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Henlius Biotech has a P/E ratio of 43.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBITDA | 29.6x | XXX | 31.9x | XXX | XXX | XXX |
| EV/EBIT | 44.4x | XXX | 45.6x | XXX | XXX | XXX |
| EV/Gross Profit | 8.2x | XXX | 10.2x | XXX | XXX | XXX |
| P/E | 43.3x | XXX | 48.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 105.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Henlius Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Henlius Biotech Margins & Growth Rates
Henlius Biotech's revenue in the last 12 month grew by 12%.
Henlius Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Henlius Biotech's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Henlius Biotech's rule of X is 68% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Henlius Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | (6%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 68% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 32% | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Henlius Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Henlius Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Hebei Changshan | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Erasca | XXX | XXX | XXX | XXX | XXX | XXX |
| Mirum Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Celcuity | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Henlius Biotech M&A Activity
Henlius Biotech acquired XXX companies to date.
Last acquisition by Henlius Biotech was on XXXXXXXX, XXXXX. Henlius Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Henlius Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHenlius Biotech Investment Activity
Henlius Biotech invested in XXX companies to date.
Henlius Biotech made its latest investment on XXXXXXXX, XXXXX. Henlius Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Henlius Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Henlius Biotech
| When was Henlius Biotech founded? | Henlius Biotech was founded in 2010. |
| Where is Henlius Biotech headquartered? | Henlius Biotech is headquartered in China. |
| How many employees does Henlius Biotech have? | As of today, Henlius Biotech has over 3K employees. |
| Who is the CEO of Henlius Biotech? | Henlius Biotech's CEO is Jun Zhu. |
| Is Henlius Biotech publicly listed? | Yes, Henlius Biotech is a public company listed on HKEX. |
| What is the stock symbol of Henlius Biotech? | Henlius Biotech trades under 02696 ticker. |
| When did Henlius Biotech go public? | Henlius Biotech went public in 2019. |
| Who are competitors of Henlius Biotech? | Henlius Biotech main competitors are Hebei Changshan, Abbott India, Erasca, Mirum Pharmaceuticals. |
| What is the current market cap of Henlius Biotech? | Henlius Biotech's current market cap is $6B. |
| What is the current revenue of Henlius Biotech? | Henlius Biotech's last 12 months revenue is $1B. |
| What is the current revenue growth of Henlius Biotech? | Henlius Biotech revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Henlius Biotech? | Current revenue multiple of Henlius Biotech is 6.2x. |
| Is Henlius Biotech profitable? | Yes, Henlius Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Henlius Biotech? | Henlius Biotech's last 12 months EBITDA is $212M. |
| What is Henlius Biotech's EBITDA margin? | Henlius Biotech's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Henlius Biotech? | Current EBITDA multiple of Henlius Biotech is 29.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.